Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Event: Regulation FD Disclosure regarding an updated corporate overview presentation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the availability of an updated corporate presentation and does not contain financial statements or quantitative performance data.
Material Changes
No material financial changes versus prior periods are reported in this document. The only disclosed change is the update to the Company's corporate overview presentation.
Guidance, Outlook, and Risks
Management Commentary: The Company updated its corporate overview presentation, which is furnished as Exhibit 99.1 and available on the Company's website.
Legal Status of Information: In accordance with General Instruction B.2 of Form 8-K, the information in the corporate presentation is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liability of that section. It is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Company Presentation) for updated strategic or operational details.
- Verify the content of the presentation on the Company's official website.
- Note that the presentation content is not legally "filed" and carries different liability standards than the 8-K itself.
- Consult the most recent 10-K or 10-Q for actual financial metrics, as this 8-K contains none.